harvardbioscience.com (HBIO): Earnings per share for the last twelve months

Stable cash flow from laboratory pump sales creates a reliable foundation for Harvard Bioscience (HBIO). The rolling annual EPS trend clearly demonstrates this dynamic, where -2.62 characterizes this valuation parameter. Growth is driven by equipment deliveries to global universities, while high margins are achieved through the mass production of unique instruments for biomedical research.

HBIO Harvard Bioscience Inc. Net earnings per share for the last four quarters (07/04/2022 - 11/12/2026)

Analytical breakdowns for harvardbioscience.com (HBIO)

- stock price and consensus target price:

Stock Price Harvard Bioscience|HBIO - Analyst Median Target

- stock exchange capitalization data:

Market Value Harvard Bioscience, Inc.|HBIO - Business Value

- shareholders' equity book value data:

Net Assets per Single Share Harvard Bioscience|HBIO - Book Valuation of Business|Market Cap to Net Assets Ratio harvardbioscience.com|HBIO - Aggregate Business Assets

- debt burden and liquidity indicators:

Debt to Equity Harvard Bioscience|HBIO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Harvard Bioscience, Inc.|HBIO - Company Aggregate Debts|Debt to Book Capitalization Ratio Harvard Bioscience, Inc.|HBIO - Company Long-Term Liabilities|Company Short-Term Debts Harvard Bioscience|Quick Liquidity harvardbioscience.com

- earnings and multiples data:

HBIO - Company Profit|Future Profit Harvard Bioscience|HBIO - Market Price to Net Income Ratio|Future Price to Earnings Harvard Bioscience|HBIO - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Harvard Bioscience, Inc.|HBIO - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Harvard Bioscience|HBIO - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months harvardbioscience.com|HBIO - Earnings per share increase in current year|Expected earnings per share growth for next year Harvard Bioscience

Analysis of all company metrics:HBIO - Harvard Bioscience

Mass-produced product of Harvard Bioscience Inc.

Harvard Bioscience is scaling its scientific equipment catalog by introducing organoid analysis systems to increase margins on B2B deals. By analyzing the TTM net income per share, an investor can see the business's actual earnings distributed across the total shares outstanding. This metric eliminates the influence of total capital volume, revealing the true efficiency of profit generation. The indicator's trend highlights resource accumulation phases during periods of market lull, allowing for an objective assessment of the asset's growth potential or stagnation risk.

Competitor analysis